Journal List > Diabetes Metab J > v.40(2) > 1084877

See the article "".
Kim: Letter: The Association of Serum Cystatin C with Glycosylated Hemoglobin in Korean Adults (Diabetes Metab J 2016;40:62-9)
Cystatin C is a more sensitive indicator of mild renal impairment and better estimates the glomerular filtration rate than serum creatinine [1]. Recently, cystatin C has been suggested to provide information beyond renal function. Several studies suggested that cystatin C is associated with obesity, atherosclerosis, insulin resistance, and hypertension [23]. Furthermore, in Western populations, elevated levels of serum cystatin C are associated with prediabetes or diabetes [456].
In this article entitled "The association of serum cystatin C with glycosylated hemoglobin in Korean adults," Sim et al. [7] evaluated the association between cystatin C and prevalence of diabetic conditions defined by glycosylated hemoglobin (HbA1c) levels in Korean adults. They described that higher levels of serum cystatin C are associated with an increased prevalence of diabetic conditions in Korean adults. Interestingly, the positive association between cystatin C and diabetic conditions was not significant in the multivariable models, and this result was consistent with a previous study [6]. Although the ethnic differences in this association are not fully understood, the association between cystatin C and diabetic conditions may be weaker in Asian populations compared to white populations. However, there are several issues that need to be discussed.
First, Sabanayagam et al. [6] examined the association between serum cystatin C and prediabetes in non-obese United States adults. They examined 2,033 participants from the National Health and Nutrition Examination Survey 1999 to 2002, aged ≥20 years who were free of diabetes mellitus and chronic kidney disease. Compared to those with cystatin C in the lowest quartile (quartile 1), the multivariate odds ratio (OR) of prediabetes among those in the highest quartile (quartile 4) was 2.08 (95% confidence interval [CI], 1.09 to 3.97; P for trend=0.02). The interesting point was that an inverse association was observed between cystatin C and prediabetes in quartile 2 (OR, 0.58; 95% CI, 0.37 to 0.89). In subgroup analysis, this inverse association in quartile 2 was significant in men and other race-ethnicities. In this study, the relative risk of subjects in the group with the fourth serum cystatin C levels (fourth=1.0 mg/L) for the presence of diabetic conditions was significantly decreased compared to the lowest group (first <0.8 mg/L) in the multivariable model (OR, 0.61; 95% CI, 0.39 to 0.97; P=0.037). Furthermore, this inverse association was also significant in men (OR, 0.48; 95% CI, 0.26 to 0.88; P=0.019). These results are compatible with the aforementioned study [6] but the reason for inverse association remains unclear.
Second, specific conditions such as severe anemia and diseases that change erythrocyte lifespan should be excluded. HbA1c has been proposed as a diagnostic tool to identify people with undiagnosed diabetes or those who are at risk of diabetes [8]. The HbA1c test is a very attractive test for the diagnosis of diabetes and prediabetes because it is easy, reproducible, and reflects the mean blood glucose levels over a period of time [89]. However, the HbA1c is affected not only by age and race but also by various diseases such as anemia, liver cirrhosis, and chronic kidney disease [10]. Analyzing the patients without diseases that can potentially affect HbA1c level would be more appropriate to evaluate the association between cystatin C and prevalence of diabetic conditions defined by HbA1c levels.

Notes

CONFLICTS OF INTEREST No potential conflict of interest relevant to this article was reported.

References

1. Sarnak MJ, Katz R, Stehman-Breen CO, Fried LF, Jenny NS, Psaty BM, Newman AB, Siscovick D, Shlipak MG. Cardiovascular Health Study. Cystatin C concentration as a risk factor for heart failure in older adults. Ann Intern Med. 2005; 142:497–505.
2. Servais A, Giral P, Bernard M, Bruckert E, Deray G, Isnard Bagnis C. Is serum cystatin-C a reliable marker for metabolic syndrome? Am J Med. 2008; 121:426–432.
3. Shankar A, Teppala S. Relationship between body mass index and high cystatin levels among US adults. J Clin Hypertens (Greenwich). 2011; 13:925–930.
4. Donahue RP, Stranges S, Rejman K, Rafalson LB, Dmochowski J, Trevisan M. Elevated cystatin C concentration and progression to pre-diabetes: the Western New York study. Diabetes Care. 2007; 30:1724–1729.
5. Sahakyan K, Lee KE, Shankar A, Klein R. Serum cystatin C and the incidence of type 2 diabetes mellitus. Diabetologia. 2011; 54:1335–1340.
6. Sabanayagam C, Wong TY, Xiao J, Shankar A. Serum cystatin C and prediabetes in non-obese US adults. Eur J Epidemiol. 2013; 28:311–316.
7. Sim EH, Lee HW, Choi HJ, Jeong DW, Son SM, Kang YH. The association of serum cystatin C with glycosylated hemoglobin in Korean adults. Diabetes Metab J. 2016; 40:62–69.
8. American Diabetes Association. Classification and diagnosis of diabetes. Diabetes Care. 2015; 38:Suppl 1. S8–S16.
9. International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009; 32:1327–1334.
10. Hare MJ, Shaw JE, Zimmet PZ. Current controversies in the use of haemoglobin A1c. J Intern Med. 2012; 271:227–236.
TOOLS
ORCID iDs

Kyung-Soo Kim
https://orcid.org/http://orcid.org/0000-0002-7738-2284

Similar articles